iTrack™ Canaloplasty to be Featured at the 2025 American Glaucoma Society (AGS) Annual Meeting

California, USA, February 11, 2025 – Nova Eye Medical Limited, a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to announce that the Company's proprietary iTrack™ canaloplasty technology will be featured in numerous presentations and posters during the official scientific program of the 2025 American Glaucoma Society (AGS) Annual Meeting, taking place in Washington, DC, February 26 – March 2, 2025.

The AGS is the preeminent glaucoma-focused society in the USA, comprising more than 1600 fellowship trained glaucoma specialists and scientists active in glaucoma research.

"As demonstrated by the comprehensive range of podium and poster presentations at the 2025 American Glaucoma Society (AGS) Annual Meeting, the clinical evidence from the iTrack™ Registry study, an ongoing real-world prospective study conducted in collaboration of the IGSR co-founded by Prof. Keith Barton and Dr. Kerr, is gaining significant traction within the glaucoma community. Canaloplasty continues to prove its value as a safe and effective MIGS option for the reduction of intraocular pressure across a spectrum of glaucoma types and severities," said Kate Hunt, Chief Commercial Officer of Nova Eye.

A summary of the AGS 2025 presentations and posters featuring the iTrack™ and the iTrack™ Advance is included below:

Podium Presentations:

Thursday, February 27 **10:10 AM - 11:10 AM**

Shamil Patel
Safety and Efficacy of Ab-Interno Canaloplasty (ABiC) Using the iTrack in Angle Closure Glaucoma: 12-Month Results

Poster Presentations:

Thursday, February 27 **8:00 AM - 9:00 AM**

Shamil Patel
24-Month Results of iTrack Global Data Registry to Support the Role of Canaloplasty for Treatment of Glaucoma

Shamil Patel
Canaloplasty Effectiveness Correlated with Viscoelastic Volume Delivered in Schlemm's Canal

James Murphy
Efficacy and Safety of Ab-Interno Canaloplasty With and Without GATT in Glaucoma: 5-Year Outcomes

Mahmoud A. Khaimi
Evaluating Eye-by-Eye Outcomes of Standalone Ab-interno Canaloplasty for Uncontrolled Open Angle Glaucoma

Shivani Kamat
Intraocular Pressure Control and Medication Reduction in Uncontrolled Glaucoma Eyes Following Ab-Interno Canaloplasty

Shivani Kamat
Multicenter Canaloplasty Data Registry – Outcomes of Ab-Interno Canaloplasty Across Different Glaucoma Types and Severity

Mary Qiu
Clinical Outcomes and Safety Profile of Standalone Canaloplasty vs. Canaloplasty Combined with Cataract Surgery Using iTrack Microcatheter

Paul Harasymowycz
Factors to Prediction of Success of 20% Intraocular Pressure Reduction in Glaucoma Eyes Undergoing Ab-Interno Canaloplasty

Full session details can be accessed via the AGS program.

All educational content of the AGS Annual Meeting is planned by its Program Committee. The AGS do not endorse, promote, approve, or recommend the use of any products, devices, or services.

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of canaloplasty devices for the treatment of glaucoma. The Company also manufactures and sells the proprietary Molteno3® glaucoma drainage device for the treatment of severe or complex glaucoma. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

ABOUT CANALOPLASTY

First introduced in 2008, canaloplasty is a surgical treatment for glaucoma that targets the main sites of outflow resistance in the conventional outflow pathway: the trabecular meshwork, Schlemm's canal, and the distal collector channels. Based on the same principles as angioplasty, a flexible microcatheter is cannulated 360 degrees around Schlemm's canal during the procedure to manually break and remove blockages. Next, viscoelastic fluid is injected into Schlemm's canal as the microcatheter is withdrawn to dilate the distal outflow system and to improve the function of the trabecular meshwork.

The iTrack™ Advance canaloplasty device has a US Food and Drug Administration (FDA) 510(k) and CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma.

Indications for Use, US: The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for the cutting or disruption of the trabecular meshwork during goniotomy procedures. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.*

** The iTrack™ Advance cutting function (goniotomy) is a Class 1 510(k) exempt device function that is not specifically indicated for the reduction of intraocular pressure (IOP) or the treatment of open-angle glaucoma.*

Indications for Use, International: The Nova Eye iTrack™ Advance is indicated for fluid infusion or aspiration during surgery. The Nova Eye iTrack™ Advance is indicated for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma.

For additional information about the *iTrack™ Advance*, including safety information, please visit: https://itrack-advance.com

For media enquiries, please contact:
Kate Hunt: Nova Eye Chief Commercial Officer - khunt@nova-eye.com
Giorgio Pirazzini: GP Communications – giorgio@gpcommunications.eu